Redesign Science

0 followers


Redesign Science develops and applies a molecular dynamics-driven platform for in silico drug discovery against emerging drug target classes. We work in partnership with Biotech and Pharma to co-develop novel small molecule therapeutics.

Industries

Headquarters

Stage

Employees

Links

Org chart

David Rooklin

Collapse
Andrew Avorn
General Counsel
Gavin Bascom
VP Of Applications
Gavin Bascom
VP Applications
Brian Petkov
VP Methodology
Sharon Blaettler
Head Of Biology
Scott Liu
Director of Business Development
欢 刘
Director
Nathan Taylor
Senior ML Scientist